Traditional Chinese medicine composition for treating acute myocardial infarction, pharmaceutical preparation and application thereof

Abstract

The invention discloses a traditional Chinese medicine composition for treating acute myocardial infarction, a pharmaceutical preparation and application thereof and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from, by weight, 9-18 parts of ginseng, 3-6 parts of pseudo-ginseng, 9-18 parts of ligusticum wallichii, 12-24 parts of radix achyranthis bidentatae, 6-12 parts of fructus forsythiae and 9-18 parts of radix curcumae. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention has the beneficial effects that (1) the traditional Chinese medicine composition provided by the invention can reduce the myocardial infarction area after ischemia, inhibit myocardial fibrosis and improve heart structure and function changes caused by acute ischemic injury; and (2) the traditional Chinese medicine composition provided by the invention can effectively inhibit oxidative stress reaction and relieve mitochondrial injury, thereby playing a role in protecting the heart. And (3) the traditional Chinese medicine composition has the advantage of good safety and can be taken for a long time.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a traditional Chinese medicine composition, a pharmaceutical preparation and applications thereof for treating acute myocardial infarction. Background Art

[0002] Acute myocardial infarction (AMI) is experiencing a significant increase in morbidity and mortality due to the dual pressures of an aging population and the prevalence of metabolic risk factors. Western medical treatment for AMI focuses on rapidly restoring coronary blood flow and saving the dying myocardium. Primary treatments include revascularization therapies such as thrombolysis, percutaneous coronary intervention (PCI), and coronary artery bypass grafting. However, revascularization therapy itself can lead to myocardial ischemia / reperfusion injury, causing oxidative stress and mitochondrial dysfunction. Currently, there are no specific drugs that can completely block this process. Furthermore, ventricular remodeling and heart failure after AMI are key areas of long-term management and present significant challenges.

[0003] Traditional Chinese medicine, based on a holistic view and syndrome differentiation and treatment, has demonstrated unique advantages of multiple targets and multiple pathways in the prevention and treatment of AMI. By combining traditional Chinese and Western medicine, we can find safe and effective treatment methods to inhibit oxidative stress and reduce mitochondrial damage, which is of great significance for improving the structure and function of the heart after AMI, and the morbidity and mortality of cardiovascular diseases. In the existing technology, Professor Yue Meizhong's empirical formula, Ginseng Panax Notoginseng Amber Formula, has a good effect in treating AMI, but there is still room for improvement. Academician Chen Keji, a master of traditional Chinese medicine, inherited Professor Yue Meizhong's academic thinking, improved the original formula, and formed the drug of the present invention, which has been confirmed to have a good effect in treating AMI through clinical and basic research. Summary of the Invention

[0004] The object of the present invention is to provide a Chinese medicine composition, a pharmaceutical preparation and its application for treating acute myocardial infarction, so as to solve the problems raised in the above background technology.

[0005] To achieve the above object, the present invention provides the following technical solutions:

[0006] A traditional Chinese medicine composition for treating acute myocardial infarction comprises the following raw materials in parts by weight: 9-18 parts of ginseng, 3-6 parts of notoginseng, 9-18 parts of chuanxiong, 12-24 parts of cyathula, 6-12 parts of forsythia and 9-18 parts of turmeric.

[0007] As a further technical solution of the present invention, the raw materials are as follows: 9 parts by weight of ginseng, 3 parts of Panax notoginseng, 9 parts of Chuanxiong, 12 parts of Achyranthes bidentata, 6 parts of Forsythia suspensa and 9 parts of Curcuma aromatica.

[0008] A pharmaceutical preparation with the above-mentioned Chinese medicine composition as the active ingredient, wherein the pharmaceutical preparation is prepared into a common dosage form in pharmacy by conventional preparation methods in the art.

[0009] As a further technical solution of the present invention, the pharmaceutical preparation includes decoction, capsule, tablet, pill or granule.

[0010] As a further technical solution of the present invention, the pharmaceutical preparation further comprises pharmaceutically acceptable excipients.

[0011] The invention relates to an application of the above-mentioned Chinese medicine composition in treating acute myocardial infarction.

[0012] As a further technical solution of the present invention, the Chinese medicine composition is used to reduce the area of ​​myocardial infarction after ischemia and inhibit myocardial fibrosis.

[0013] As a further technical solution of the present invention, the Chinese medicine composition is used to inhibit oxidative stress reaction and alleviate mitochondrial damage.

[0014] Compared with existing technologies, the present invention has the following beneficial effects: ① The traditional Chinese medicine composition provided by the present invention can reduce the area of ​​post-ischemic myocardial infarction, inhibit myocardial fibrosis, and improve changes in cardiac structure and function caused by acute ischemic injury. ② The traditional Chinese medicine composition provided by the present invention can effectively inhibit oxidative stress and reduce mitochondrial damage, thereby exerting a cardioprotective effect. ③ The traditional Chinese medicine composition provided by the present invention has the advantage of good safety and can be taken long-term. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is a graph showing the effect of the Chinese medicinal composition on the body weight of rats with myocardial ischemia in the animal experiment of the present invention;

[0016] Figure 2 This is a graph showing the effect of the Chinese medicinal composition on cardiac ultrasound in rats with myocardial ischemia in an animal experiment of the present invention;

[0017] Figure 3 This is a graph showing the effect of the Chinese medicinal composition on the heart morphology of rats with myocardial ischemia in the animal experiment of the present invention;

[0018] Figure 4 This is a graph showing the effect of the Chinese medicinal composition on Masson staining of myocardial tissue in rats with myocardial ischemia in an animal experiment of the present invention;

[0019] Figure 5 This is a graph showing the effect of the Chinese medicinal composition on TTC staining of the heart of rats with myocardial ischemia in the animal experiment of the present invention;

[0020] Figure 6This is a graph showing the effect of the Chinese medicinal composition on HE staining of myocardial tissue in rats with myocardial ischemia in an animal experiment of the present invention;

[0021] Figure 7 This is a graph showing the effect of the Chinese medicinal composition on mitochondria in myocardial tissue of rats with myocardial ischemia in the animal experiment of the present invention. DETAILED DESCRIPTION

[0022] The following is a clear and complete description of the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative efforts are within the scope of protection of the present invention.

[0023] The present invention provides a traditional Chinese medicine composition for treating acute myocardial infarction, comprising the following raw materials in parts by weight: 9 parts of ginseng, 3 parts of Panax notoginseng, 9 parts of Chuanxiong, 12 parts of Achyranthes bidentata, 6 parts of Forsythia suspensa, and 9 parts of Curcuma zedoaria. In the formula, ginseng and Panax notoginseng serve as the main ingredients, with ginseng primarily tonifying the five internal organs, calming the spirit, and relieving palpitations; Panax notoginseng dissipates blood stasis, stops bleeding, and reduces swelling and relieves pain. Chuanxiong, Achyranthes bidentata, and Curcuma zedoaria serve as the auxiliary ingredients, with Chuanxiong promoting blood circulation and qi, dispelling wind and relieving pain; Achyranthes bidentata nourishes the liver and kidneys, strengthens tendons and bones, removes blood stasis and promotes menstruation, and guides blood downward; Curcuma zedoaria promotes qi and resolves blood stasis, clears the heart and relieves depression, and promotes bile secretion and reduces jaundice; and Forsythia suspensa serves as the adjuvant, clearing heat and detoxifying, reducing swelling and dispersing nodules. The entire formula works together to invigorate qi, activate blood circulation, and detoxify.

[0024] Experimental Example: Pharmacodynamic Study on the Chinese Medicine Composition of the Present Invention for Preventing and Treating Acute Myocardial Infarction

[0025] animal

[0026] Thirty 8-week-old Wistar rats were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd. with the experimental animal production license number: SCXK (Beijing) 2021-0011; they were raised in the Experimental Animal Center of Xiyuan Hospital, China Academy of Chinese Medical Sciences with the experimental animal use license number: SYXK (Beijing) 2023-0053.

[0027] drug

[0028] Shenqi Yangxin Recipe: 9 parts ginseng, 3 parts Panax notoginseng, 9 parts Chuanxiong, 12 parts Achyranthes, 6 parts Forsythia, and 9 parts Curcuma. Ginseng, Chuanxiong, Achyranthes, Forsythia, and Curcuma were purchased from Beijing Kangrentang Pharmaceutical Co., Ltd. [Ginseng Formula Granules (Beijing Kangrentang Pharmaceutical Co., Ltd., batch number: 23023281), Chuanxiong Formula Granules (Beijing Kangrentang Pharmaceutical Co., Ltd., batch number: 24008491), Forsythia Formula Granules (Beijing Kangrentang Pharmaceutical Co., Ltd., batch number: 23018951), Achyranthes Formula Granules (Beijing Kangrentang Pharmaceutical Co., Ltd., batch number: 24012561), Curcuma Formula Granules (Beijing Kangrentang Pharmaceutical Co., Ltd., batch number: 23015951)]. Panax notoginseng powder was purchased from China National Traditional Chinese Medicine Co., Ltd. (batch number: 740711102).

[0029] Sacubitril / valsartan sodium tablets were purchased from Novartis (Batch No.: HJ20170363).

[0030] Model building and grouping

[0031] An acute myocardial ischemic injury model was established in Wistar rats by surgical ligation of the left anterior descending coronary artery. A sham-operated group received only suture threading without ligation. Based on electrocardiographic (ECG) results and postoperative conditions, the rats were divided into five groups: model group, sacubitril / valsartan sodium group (SVST group), low-dose Shenqi Yangxin Fang group (SQYX-L group), and high-dose Shenqi Yangxin Fang group (SQYX-H group). A sham-operated group (Sham group) was also established, for a total of five groups, with six rats in each group.

[0032] Dosing and Administration: The dosage was calculated according to the rat-to-human dosage conversion method in the "Laboratory Animals and Animal Experimental Techniques" guide. The SQYX-L group received 2006.1 mg / kg / day, and the SQYX-H group received 4012.2 mg / kg / day. Shenqi Yangxin Fang was dissolved in pure water and thoroughly dissolved by ultrasonic agitation. After autoclaving, the drug was sterilized and stored at 4°C until use. The SVST group received a dose of 36 mg / kg / day. Sacubitril / valsartan sodium tablets were crushed and dissolved in pure water. After thorough dissolution by ultrasonic agitation, the drug was sterilized by autoclaving and stored at 4°C until use. The sham-operated and model groups received an equal volume of purified water by gavage. Drug intervention began after successful model establishment in each group. Rats in each group were weighed weekly, and the dosage was adjusted based on body weight changes. Drug intervention continued for 4 weeks.

[0033] Experimental tests: Echocardiography was used to evaluate cardiac function indicators (LVEF, LVFS, LVEDV, LVESV, LVDS, and LVDD). TTC / HE / Masson staining was used to observe myocardial pathological changes. The mitochondrial ROS and DCFH-DA content were detected by fluorescent probe method. Serum NT-proBNP and antioxidant indicators (SOD, NOS, and ALDH) were determined by ELISA. Transmission electron microscopy was used to observe mitochondrial ultrastructure. An ATP detection kit was used to analyze the energy metabolism level of myocardial tissue.

[0034] Experimental results:

[0035] (1) Effect of Chinese herbal medicine combination on body weight in rats with myocardial ischemia

[0036] Figure 1 The figure shows the weight changes of rats in each group. The average weight of rats in all groups before modeling (week 0) was 200 grams, and the initial conditions were the same. The Sham group had the largest weight gain, especially after the third week, with a significant growth rate, reflecting a better weight gain trend. The Model group grew relatively slowly overall, with most of the weight values ​​at a low level each week. The weight growth trends of the SVST group, SQYX-H group, and SQYX-L group were relatively similar, with small differences between the groups, but the overall growth rate was lower than that of the Sham group and higher than that of the Model group.

[0037] (2) Effects of Chinese herbal medicine combination on cardiac ultrasound in rats with myocardial ischemia

[0038] Figure 2 Table 1 and Table 2 show the echocardiographic results of rats in each group after drug intervention. Compared with the sham group, the model group had significantly decreased LVEF and LVFS (P < 0.05), while LVESV, LVEDV, LVDS, and LVDD were significantly increased (P < 0.05). After SVST and SQYX-L intervention, LVEF and LVFS were significantly increased compared with the model group (P < 0.05), while LVESV, LVEDV, LVDS, and LVDD were significantly decreased compared with the model group (P < 0.05). After SQYX-H intervention, LVESV, LVEDV, LVDS, and LVDD were significantly decreased compared with the model group (P < 0.05). Compared with the SVST group, there were no significant differences between the SQYX-L and SQYX-H groups. This suggests that SVST, SQYX-L, and SQYX-H interventions have a regulatory effect on indices related to left ventricular structure and function.

[0039] Table 1 Comparison of left ventricular structure and function in rats of each group (n=6)

[0040]

[0041] Note: Compared with Sham group* P<0.05; compared with the Model group # P<0.05

[0042] (3) Effect of Chinese herbal medicine combination on serum NT-proBNP levels in rats with myocardial ischemia

[0043] Table 2 shows the NT-proBNP test results for each group of rats. Compared with the sham group, NT-proBNP levels were increased in the Model, SVST, SQYX-L, and SQYX-H groups (P < 0.05). Compared with the Model group, NT-proBNP levels in the other treatment groups were decreased (P < 0.05), indicating that Shenqi Yangxin Recipe can improve cardiac function in MI rats. Compared with the SVST group, NT-proBNP levels were increased in the SQYX-L and SQYX-H groups (P < 0.05).

[0044] Table 2 NT-proBNP test results of rats in each group

[0045]

[0046] Note: Compared with Sham group * P<0.05; compared with the Model group # P<0.05; compared with SVST group △ P<0.05

[0047] (4) Effects of Chinese herbal medicine combination on cardiac morphology in rats with myocardial ischemia

[0048] Figure 3 Figure 3 shows the cardiac morphology of rats in each group. The cardiac morphology of rats in the sham group was normal. Compared with the sham group, rats in the model group had a large area of ​​white infarcted myocardium in the left anterior descending coronary artery region and significantly thinned ventricular walls. The white infarct area of ​​rats in each drug-treated group was smaller.

[0049] (5) Effects of Chinese herbal medicine combination on heart mass index and heart-tibia ratio in rats with myocardial ischemia

[0050] Table 3 shows the results of the heart mass index and heart-to-shin ratio (HSR) in each group of rats. Compared with the sham group, the HSR and HSR in the model, SQYX-L, and SQYX-H groups were significantly increased (P < 0.05), indicating that acute myocardial ischemia leads to abnormal increases in HSR and HSR in rats, reflecting increased heart weight and a typical manifestation of cardiac remodeling. Compared with the model group, the HSR and HSR in the SVST, SQYX-L, and SQYX-H groups were decreased to varying degrees (P < 0.05).

[0051] Table 3 Measurement results of heart mass index and heart-to-shin ratio of rats in each group

[0052]

[0053] Note: Compared with Sham group * P<0.05; compared with the Model group # P<0.05

[0054] (6) Effect of Chinese herbal medicine combination on Masson staining of myocardial tissue in rats with myocardial ischemia

[0055] Figure 4 The following are Masson-stained sections of myocardial tissue from rats in each group (×400). Masson staining revealed that the red myocardial cells in the sham group were densely and regularly arranged, with fewer blue collagen fibers, primarily distributed around blood vessels and in the interstitial spaces between myocardial cells. Compared with the sham group, the myocardial cells in the model group were disorderly arranged and significantly reduced in number. Collagen fibers proliferated in sheets or bundles, interspersed between the myocardial cells and separating them. Compared with the model group, the myocardial cells in each drug-treated group were more neatly arranged, with fewer collagen fibers.

[0056] (7) Effect of Chinese herbal medicine combination on TTC staining of myocardial ischemia rat hearts

[0057] Figure 5 The following are TTC-stained sections of myocardial tissue of rats in each group. Through TTC staining, it can be observed that the myocardial tissue of the Sham group is uniformly bright red, indicating that the myocardial cells are active and there is no infarcted area. In the myocardial tissue of the Model group, obvious pale or grayish-white areas can be seen, which form a sharp contrast with the bright red areas. The pale areas are the sites of myocardial infarction. Compared with the Sham group, the proportion of myocardial infarction area in the Model group, SQYX-H group, SQYX-L group, and SVST group was significantly increased (P<0.01). Compared with the Model group, the proportion of myocardial infarction area in the SVST group, SQYX-L group, and SQYX-H group was significantly reduced, and the differences were statistically significant (P<0.01).

[0058] Table 4 Proportion of myocardial infarction area in rats in each group by TTC staining

[0059]

[0060] Note: Compared with Sham group ** P<0.01; compared with the Sham group # P<0.05, ## P<0.01; compared with the SVST group, ^^ P<0.01

[0061] (8) Effect of Chinese herbal medicine combination on HE staining of myocardial tissue in rats with myocardial ischemia

[0062] Figure 6 HE-stained sections of myocardial tissue from rats in each group (×400) were obtained. HE staining revealed that myocardial cells in the sham group were tightly and neatly arranged, with regular cell morphology, clear nuclei of uniform size, and uniform cytoplasmic staining. No obvious inflammatory cell infiltration or tissue damage was observed. Compared with the sham group, myocardial tissue in the model group showed significant texture disorder, a decrease in the number of myocardial cells, and loose and disordered arrangement. Some myocardial cells were swollen and deformed, with pyknosis and fragmentation of the nuclei, and uneven cytoplasmic staining, accompanied by a large amount of inflammatory cell infiltration and collagen fiber deposition. Compared with the model group, the structural and arrangement integrity of myocardial cells in all drug-treated groups was preserved, and inflammatory cell infiltration and collagen fiber deposition were alleviated to varying degrees.

[0063] (9) Effects of Chinese herbal medicine combination on mitochondrial reactive oxygen species in myocardial tissue of rats with myocardial ischemia

[0064] Table 5 shows the results of mitochondrial ROS determination in rats of each group. The peak values ​​of the spike graphs of each sample in the Sham group were relatively stable, and the scatter plot distribution was also relatively concentrated, indicating that the mitochondrial ROS level of the rats in this group was relatively stable with small fluctuations. The peak value of the spike graph and the scatter plot distribution of the SVST group changed to a certain extent compared with the Sham group, suggesting that the positive drug may have an effect on the mitochondrial ROS level and regulate the ROS level to a certain extent. The peak value of the spike graph in the Model group was relatively high, and the scatter plot distribution range was wider, indicating that the mitochondrial ROS level of the rats in this group was high and the individual differences were large. Acute myocardial ischemia may have caused an increase in ROS levels. Compared with the Model group, the peak values ​​of the spike graphs of the SQYX-L group and the SQYX-H group were reduced, and the scatter plot distribution also changed, indicating that Shenqi Yangxin Decoction may have the effect of reducing mitochondrial ROS levels, and the effect of the SQYX-L group was more obvious.

[0065] Table 5 Mitochondrial ROS determination results of rats in each group

[0066]

[0067] The mean 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) level in the sham group was 1855.833 μmol / L, with a small standard deviation, indicating relatively low DCFH-DA levels in this group and minimal individual variability. The mean level in the SVST group was 2026.500 μmol / L, slightly higher than in the sham group, with a larger standard deviation, suggesting that the positive drug has a certain effect on DCFH-DA levels and that individual variability is large. The mean level in the model group was as high as 2841.833 μmol / L, significantly higher than in the sham group, indicating that modeling treatment significantly increased DCFH-DA levels. The mean level in the SQYX-H group was 2399.167 μmol / L, a decrease compared to the model group, indicating that high-dose Shenqi Yangxin Formula can reduce DCFH-DA levels. The mean level in the SQYX-L group was 2156.667 μmol / L, lower than in both the SQYX-H and model groups, suggesting that low-dose Shenqi Yangxin Formula is more effective in reducing DCFH-DA levels.

[0068] Table 6 Detection of mitochondrial DCFH-DA fluorescence probe in rats in each group

[0069]

[0070] (10) Effect of Chinese herbal medicine combination on antioxidant capacity in rats with myocardial ischemia

[0071] Table 7 shows the antioxidant serum indices of rats in each group. Compared with the sham group, the Model group showed a significant decrease in SOD, NOS, and ALDH (P < 0.01), indicating that modeling resulted in damage to the rats' antioxidant defense system. Compared with the Model group, the SVST, SQYX-L, and SQYX-H groups showed a significant increase in SOD, NOS, and ALDH (P < 0.01).

[0072] Table 7 Antioxidant serum indexes of rats in each group

[0073]

[0074] Note: Compared with the Sham group, * P<0.05, ** P<0.01; compared with the Model group, # P<0.05, ## P<0.01; compared with the SVST group, ^^P<0.01

[0075] (11) Effects of Chinese herbal medicine combination on mitochondria in rats with myocardial ischemia

[0076] Figure 7Figure 2 shows the mitochondrial morphology of rats in the SVST group under transmission electron microscopy. Mitochondria in the sham group showed relatively regular morphology, mostly oval or rod-shaped, with clear, dense, and neatly arranged mitochondrial cristae, and uniform matrix electron density, indicating normal mitochondrial structure and good function. Mitochondria in the model group showed significant morphological abnormalities, including swelling and deformation, fractured, reduced, or even absent mitochondrial cristae, and decreased and uneven matrix electron density, indicating severe mitochondrial damage and possible functional impairment after myocardial infarction. Mitochondrial morphology improved in the SVST group, but some mitochondria were still swollen. The number of cristae was less than that in the sham group, but clearer and more regularly arranged than in the model group. Mitochondrial swelling was further reduced in the SQYX-H group, with relatively intact cristae and neatly arranged cristae. Mitochondrial morphology in the SQYX-L group was similar to that of the sham group, with most mitochondria exhibiting normal oval or rod-shaped shapes, clear, densely arranged, and neatly arranged cristae, and uniform matrix electron density. This indicates that low-dose Shenqi Yangxin Recipe significantly repairs mitochondrial lesions after myocardial infarction and effectively improves mitochondrial structure and function.

[0077] Table 8 Results of ATP content measurement in myocardial tissue of rats in each group. Compared with the Model group, the ATP content in the SVST, SQYX-L, and SQYX-H groups was significantly increased (P < 0.01). The ATP content in the SVST, SQYX-L, and SQYX-H groups was significantly increased, indicating that both Sacubitril-Valsartan Sodium Tablets and Shenqi Yangxin Recipe can effectively improve the ATP metabolism level of model rats and have a repair effect on the ATP reduction caused by the disease model. The intervention measures have positive therapeutic significance.

[0078] Table 8 Determination of ATP content in myocardial tissue of rats in each group

[0079]

[0080] Note: Compared with the Sham group, * P<0.05, ** P<0.01; compared with the Model group, # P<0.05, ## P<0.01; compared with the SVST group, ^^P<0.01

[0081] Conclusion: This study, using a rat model of myocardial infarction and intervention with a traditional Chinese medicine composition, confirmed the protective effects of the composition on cardiac structure and function following acute myocardial ischemia. The composition inhibited oxidative stress and reduced mitochondrial damage, thereby exerting a cardioprotective effect. It also reduced the size of myocardial infarction and inhibited myocardial fibrosis, providing experimental support for the clinical diagnosis and treatment of this disease.

[0082] In addition, it should be noted that, based on the above-mentioned basic drug ratio, technical personnel in this field have conducted multiple groups of experiments within the ratio range of 9-18 parts of ginseng, 3-6 parts of Panax notoginseng, 9-18 parts of Chuanxiong, 12-24 parts of Achyranthes bidentata, 6-12 parts of Forsythia suspensa and 9-18 parts of Curcuma aromatica, and the technical effects required to be achieved by different drug ratios can all be supported by experiments.

[0083] A pharmaceutical preparation comprising the aforementioned traditional Chinese medicine composition as an active ingredient is prepared using conventional methods in the art into a commonly used pharmaceutical dosage form. The pharmaceutical preparation includes a decoction, capsule, tablet, pill, or granule. The pharmaceutical preparation also includes pharmaceutically acceptable excipients.

[0084] A use of the aforementioned traditional Chinese medicine composition for the treatment of acute myocardial infarction. The composition can reduce the area of ​​post-ischemic myocardial infarction, inhibit myocardial fibrosis, and improve changes in cardiac structure and function caused by acute ischemic injury. The composition can effectively inhibit oxidative stress and reduce mitochondrial damage, thereby exerting a cardioprotective effect.

[0085] It will be apparent to those skilled in the art that the present invention is not limited to the details of the exemplary embodiments described above and that the invention can be embodied in other specific forms without departing from the spirit or essential characteristics of the invention. Therefore, the embodiments should be considered in all respects as illustrative and non-restrictive, and the scope of the invention is defined by the appended claims, not the foregoing description, and all variations within the meaning and range of equivalents of the claims are intended to be included therein. Any reference sign in a claim should not be construed as limiting the claim to which it relates.

[0086] In addition, it should be understood that although this specification is described in terms of implementation methods, not every implementation method contains only one independent technical solution. This narrative method of the specification is only for the sake of clarity. Those skilled in the art should regard the specification as a whole. The technical solutions in each embodiment can also be appropriately combined to form other implementation methods that can be understood by those skilled in the art.

Claims

1. A Chinese medicine composition for treating acute myocardial infarction, characterized in that: The invention comprises the following raw materials in parts by weight: 9-18 parts of ginseng, 3-6 parts of notoginseng, 9-18 parts of chuanxiong, 12-24 parts of cyathula, 6-12 parts of forsythia and 9-18 parts of turmeric.

2. A Chinese medicine composition for treating acute myocardial infarction according to claim 1, characterized in that, The invention comprises the following raw materials in parts by weight: 9 parts of ginseng, 3 parts of notoginseng, 9 parts of ligusticum chuanxiong, 12 parts of cyathula, 6 parts of forsythia and 9 parts of turmeric.

3. A pharmaceutical preparation comprising the Chinese medicine composition for treating acute myocardial infarction according to claim 1 or 2 as an active ingredient, characterized in that: The pharmaceutical preparation is prepared into a common dosage form in pharmacy by conventional preparation methods in the art.

4. The pharmaceutical preparation according to claim 3, characterized in that The pharmaceutical preparations include decoctions, capsules, tablets, pills or granules.

5. The pharmaceutical preparation according to claim 4, characterized in that The pharmaceutical preparation also includes pharmaceutically acceptable excipients.

6. Use of the Chinese medicine composition according to claim 1 or 2 in treating acute myocardial infarction.

7. The use according to claim 6, characterized in that The traditional Chinese medicine composition is used for reducing the area of ​​myocardial infarction after ischemia and inhibiting myocardial fibrosis.

8. The use according to claim 6, characterized in that The traditional Chinese medicine composition is used for inhibiting oxidative stress reaction and alleviating mitochondrial damage.

Images